chrisvoncsefalvay/vaers-outcomes huggingface dataset:
On March 22nd (8 days after the vaccination I noticed a red bump on my right eyebrow that itched. At first, I thought it was an insect bite. Today, March 22rd, I noticed a red rash on my face (similar to rosacea). My cheeks and ears feel warm to the touch, and I have a mild itch on the entire  area. The rash is more prominent on the right side of the face. This has not happened to me before. I am planning on taking an OTC antiallergic to calm the symptoms.
Confusion, Headache, Myalgia, Fever, Diarrhea & NauseaVomiting Narrative:
I woke up on 3/7 right ear hurting, head throbbing felt warm with no temp.On 3/10 I went to the school nurse at my employer stated my right ear was red call doctor for antibiotic. I did contact my doctor the symptoms I was exp by then my tooth (bottom right side) was hurting diagnosed trigeminal neuralgia. On last 3/17 my tooth/ear was still exp pain I followed up with my dentist stated he dint see anything. Then on 3/20 I exp a lot of pain went to ER had a CT and concluded I do have trigeminal  neuralgia was told to follow up with neuro surgeon.
Hives were noticed in the middle of the night. Raised red hives were itchy, but originally ignored as possible bug bites. Next morning there were a few more, but again ignored. Later that night, many hives were noticed on both left and right arms, which is when Equate nondrowsy antihistamine was taken. Extreme itchiness and redness was also at the area. Within an hour of taking the antihistamine, hives went down. The following day, no hives were visible. On the morning of 1/19/22, hives were once again present, but this time on the legs. The antihistamine once again was taken to reduce symptoms.
One day after flu shot I became very depressed not even being able to respond to any questions my wife asked me. This lasted most of that day. Two days after shot, I was nearly unable to walk for several days due to severe back pain. I had to walk with two canes.
10-10-07 0030 received Influenza vaccine IM. 0100 - developed hives on arm and shortness of breath. Throat started to close. 0105 - seen in emergency room - 0.3cc (1:1000) Epinephrine SQ given at 0115.
Area of shot made the area very pink and slightly swollen, its a week and its still red and swollen no other symptoms.
MEDI-0002780 is not a serious spontaneous case from a consumer in the USA of involving muscle ache:(labeled, USA). The reporter causality is not provided to FluMist. Case reference MEDI0002780 is a spontaneous case report sent by a consumer that refers to a male age 38 years. The patient's past medical history included rosacea. He received FluMist on 01/22/2005 at 9:00 in the morning. The patients concomitant medication included multivitamins. When the patient awoke at 5:30 in the morning of 01/023/2005, the patient had difficulty getting out of bed due to muscle ache and pain. By the afternoon the patient had a fever of 103 degrees Fahrenheit, chills, and a runny nose. The patient received acetaminophen for treatment. As of 01/24/2005 the events had not resolved.
I started with some sneezing about a week and they was followed the next day with a really bad runny noes and head congestion I got a scratchy throat with a dry cough and that went on Thursday and Friday, I tested positive Friday and got paxlosive. I started to get a little bit of chest congestion and that went into Saturday and Sunday. And then I started to feel better the running nose stopped and I still had a cough but no scratchy throat. Today I feel okay but I still have chest congestion and a cough. I never had a fever.
pt became pale, diaphoretic & c/o feeling dizzy w/in 3min of recv vax;also became hypotensive BP 90/60-100/70 p/episode;
rash; This is a spontaneous report from a non-contactable consumer (patient) via a Pfizer sponsored program Pfizer First Connect. A female patient of an unspecified age received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection, batch/lot number and expiration date was not reported), via an unspecified route of administration on an unspecified date as dose number unknown, single for COVID-19 immunisation. The patient's medical history and concomitant medications were not reported. The patient experienced rash on an unspecified date. The outcome of event was unknown.  No follow-up attempts are possible. Information about lot/batch number cannot be obtained.
Patient reported on 9/10/10 that after receiving ZOSTAVAX on 9/3/10, she had large swelling, redness, and pain at injection site and developed blisters around the site. Also reported flu-like symptoms with body aches. She stated all symptoms were improving slowly. Swelling and redness were minimal at time of reporting and blisters were mostly healed.
Booster dose; temperature; Flu like symptoms; Headache; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) from medical information team. The reporter is the patient.  A 49 year-old female patient received bnt162b2 (BNT162B2), administration date 20Dec2021 (Batch/Lot number: unknown) as dose 3 (booster), single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Bnt162b2 (Dose: 1, After first one, I was little bit tried but I didn't have any flu like symptoms or anything), administration date: 10Apr2021, for COVID-19 Immunization, reaction(s): "Little bit tired"; Bnt162b2 (Dose: 2), administration date: 29Apr2021, for COVID-19 Immunization, reaction(s): "Mild joint pain", "Felt tired". The following information was reported: IMMUNISATION (non-serious) with onset 20Dec2021, outcome "unknown", described as "Booster dose"; BODY TEMPERATURE (non-serious) with onset Dec2021, outcome "unknown", described as "temperature"; INFLUENZA LIKE ILLNESS (non-serious) with onset Dec2021, outcome "unknown", described as "Flu like symptoms"; HEADACHE (non-serious) with onset Dec2021, outcome "unknown", described as "Headache".  The lot number for bnt162b2 was not provided and will be requested during follow up.
PATIENT RECEIVED VACCINE FROM OUTSIDE SOURCE HYPOTENSION HYPOXEMIA 5/31/2022  --  RECURRENCE OF HOSPITALIZATION WITH SAME SYMPTOMS
C/O soreness at site of Influenza 2011-2012 vaccine. Also c/o soreness with any movement of (L) arm. Describes pain as 9 out of 10 with movement. Advised 8-10 days Ibuprofen recheck if persists. Examined by FNP.
2cm shingles-like rash with vesicles, redness and mild tenderness.
Today, 10-4-2022 I gave Pt, who is 6 years of age, a Covid vaccine for ages 6m to 4 years.
The vaccine syringe was faulty and upon administration vaccine spurted out of the neck of the prefilled syringe collar. The needle was fitted tightly and appropriately onto the luer lock. We reported this to the manufacturer.
196 patients received 0.25mL of Moderna Covid-19 Vaccine, Bivalent; No adverse event; This spontaneous case was reported by an other health care professional and describes the occurrence of UNDERDOSE (196 patients received 0.25mL of Moderna Covid-19 Vaccine, Bivalent) and NO ADVERSE EVENT (No adverse event) in an adult patient of an unknown gender who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) for COVID-19 prophylaxis.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) .25 milliliter. On an unknown date, the patient experienced UNDERDOSE (196 patients received 0.25mL of Moderna Covid-19 Vaccine, Bivalent) and NO ADVERSE EVENT (No adverse event). At the time of the report, UNDERDOSE (196 patients received 0.25mL of Moderna Covid-19 Vaccine, Bivalent) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for UNDERDOSE (196 patients received 0.25mL of Moderna Covid-19 Vaccine, Bivalent).    No concomitant drug information was provided.  It was unknown if the patient had received any other vaccine 4 weeks prior to COVID-19 vaccine.  No treatment drug information was provided.   This case was linked to US-MODERNATX, INC.-MOD-2022-689916 (Linked Report).   Most recent FOLLOW-UP information incorporated above includes: On 27-Dec-2022: Follow up received wherein the patient age group and narrative updated.; Sender's Comments:  US-MODERNATX, INC.-MOD-2022-689916:
Within 1 hour left arm felt very stiff and sore from shoulder to elbow. Within 90 minutes stiffness traveled to wrist as well, and any movement that involved moving any part of the arm up or out away from the body was excruciating. On a scale of 1-10 the pain was at least an 8, and was a shooting, searing, sharp pain originating from elbow/shoulder joints.  The injection site was extremely painful to the touch, but even the smallest physical movement of any part of the arm became impossible without extreme pain.  Injection site was painful to the touch for 72hrs.  Extreme pain from movement  in entire arm decreased from an 8 to a 5 by 9am the following day. Within 48hrs of the injection the sharp pain during movement could only be felt  in the joints of the arm, primarily elbow and shoulder.  *Besides injection reaction, entire body (all joints) was extremely achy, similar to ache from strep, flu, infection.  Very fatigued for 24hrs. General fatigue and joint aches and pain subsided after 72hrs.
Coughing, vomiting, right-sided chest pain, nausea, body aches and chills, hospitalization.
Itchiness; pain; Little swollen; red; lump; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE PAIN (pain), VACCINATION SITE MASS (lump), VACCINATION SITE SWELLING (Little swollen), VACCINATION SITE ERYTHEMA (red) and VACCINATION SITE PRURITUS (Itchiness) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included No adverse event.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 18-Apr-2021, the patient experienced VACCINATION SITE PAIN (pain), VACCINATION SITE MASS (lump), VACCINATION SITE SWELLING (Little swollen) and VACCINATION SITE ERYTHEMA (red). On 19-Apr-2021, the patient experienced VACCINATION SITE PRURITUS (Itchiness). At the time of the report, VACCINATION SITE PAIN (pain), VACCINATION SITE MASS (lump), VACCINATION SITE SWELLING (Little swollen), VACCINATION SITE ERYTHEMA (red) and VACCINATION SITE PRURITUS (Itchiness) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.
3days p/vax pt generalized tonic clonic seizure lasting 30 sec. post ictal x15 minutes
Pt received  4 vaccines for training assignment to Korea. Pt developed light headedness, dizziness, and nausea one minute after administration. Pt was treated for vasovagal episode. Pt was advised to lay down with legs bent. Technician applied ice pack on pt's chest. Pt's vitals were assessed every 5 minutes. Pt's vitals were normal. Pt was discharged 15 minutes after all symptoms have subsided.
woke up with a fast heart beat; fever; head ache; This spontaneous case was reported by a consumer and describes the occurrence of HEART RATE INCREASED (woke up with a fast heart beat), PYREXIA (fever) and HEADACHE (head ache) in a 22-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 016B21A) for COVID-19 vaccination.     The patient's past medical history included No adverse event.    On 30-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 31-Mar-2021, the patient experienced PYREXIA (fever) and HEADACHE (head ache). On 02-Apr-2021, the patient experienced HEART RATE INCREASED (woke up with a fast heart beat). On 31-Mar-2021, PYREXIA (fever) and HEADACHE (head ache) had resolved. At the time of the report, HEART RATE INCREASED (woke up with a fast heart beat) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No treatment details were reported
Hives covering entire body, chills, fever (101 degrees), nausea and vomiting, headache, joint aches.
Flushing nearly 4 hours after injection. Also feeling hot, and a flush-like rash (no welts or raised bumps) on upper chest and back only. No itching, pain, aches, shortness of breath, nausea or headache.
Day 3 post vaccine: muscle soreness all over body, and beginnings of severe  lower right back/upper thigh pain and fever/chills.  On Sept 9th through 15th I experienced a massive headache that culminated in blinding, disorienting headache unresponsive to acetaminophin and aspirin combinations.   Simultaneously with the headache,  fever of up to 101.7 (up from a normal of 97.7) spiked and severe, uncontrollable chills and shaking persisted. On  9/16 awoke unable to walk with EXCRUCIATING PAIN in right hip/lower back and right thigh. Could not get out of bed or move for ANY reason without crying out in pain. Could not get out of bed for any reason.   Any body movement (including arms) triggered massive stabbing, electric shock down right leg and was so terrible it caused screams of pain.   Was told to take Tylenol at max dosage, which did nothing, and toughed it out for next 7 days.  Prednizone and Tramadol were prescribed  about 24th, and incredible pain persisted despite these drugs.  Called 911 and was transported by medics to Allenmore hospital in Tacoma on  .  Blood work showed slightly elevated white blood cell counts.  Doxicycline was prescribed. Continues to be bedridden currently and in excrutiating pain still, 4 weeks and 2 days later.
Patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion); Patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion); This spontaneous case was reported by an other health care professional and describes the occurrence of POOR QUALITY PRODUCT ADMINISTERED (Patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)) and PRODUCT TEMPERATURE EXCURSION ISSUE (Patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)) in a 61-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .25 milliliter. On an unknown date, the patient experienced POOR QUALITY PRODUCT ADMINISTERED (Patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)) and PRODUCT TEMPERATURE EXCURSION ISSUE (Patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)). At the time of the report, POOR QUALITY PRODUCT ADMINISTERED (Patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)) and PRODUCT TEMPERATURE EXCURSION ISSUE (Patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)) outcome was unknown.     For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications information was not reported. The reporter stated that because their facility has not been able to download the digital data logger, they have been put on hold at the moment and cannot administer the Moderna COVID-19 vaccine to patients until an assessment was made.  There had been no power outages that would have impacted the Moderna vaccine. However, she reiterates that because her facility was unable to download the digital data logger, they would need to treat this issue as a temperature excursion.  Reporter stated that no adverse reactions were reported by any patients.
Patient had chest pain that required him to be admitted to the hospital with a diagnosis of pericarditis-myocaraditis. He was started on indomethacin 1/18 with recurrent pain overnight - med was increased and pain was relieved with Toradol and colchine was added. Currently still inpatient.
Child found unresponsive at 0450 am on 9/26/18 and EMS called immediately. CPR was initiated. Child was last seen breathing at midnight. Child taken to the emergency department at hospital. Child pronounced dead at 5:44 am.
Some pimples in the back.; This is a spontaneous report from a contactable consumer, the patient. A 35-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6202) via an unspecified route of administration in the left arm on 01Mar2021 at 11:45 (at the age of 35-years-old) as a single dose for COVID-19 immunisation. The patient did not have any medical history. The patient had no allergies to medications, food, or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient did not receive any other medications within 2 weeks of vaccination. On 01Mar2021 at 00:00, the patient experienced some pimples in the back and had no pain. No therapeutic measures were taken as a result of the event. Since the vaccination, it was unknown whether the patient had been tested for COVID-19. The clinical outcome of the event some pimples in the back was not recovered at the time of this report.  No follow-up attempts are needed. No further information is expected.
Patient developed hive like rash from scalp to chin on face. Her front part of neck was covered in rash also. 2 days later rash changed to an eczema type rash and she continues to have eczema 4 days later, on cheeks, part of forehead, chin, and neck.
mild arm pain; This is a spontaneous report from a contactable consumer (patient). A 68-year-old male patient received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE; Lot number: not provided), via an unspecified route of administration on 19Jan2021 at single dose for COVID-19 immunization. The patient's medical history and concomitant medications were not reported. The patient received the first dose yesterday (19Jan2021), only reporting mild arm pain. The patient wanted to know if the first and second dose are identical. Outcome of the event was unknown.  Information on the lot/ batch number has been requested.
Treatment of COVID-19; Treatment of COVID-19; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 73-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), on 24Feb2021 as dose 1, single (Batch/Lot number: unknown), in left arm, on 17Mar2021 as dose 2, single (Batch/Lot number: unknown), in right arm and on 19Oct2021 as dose 3 (booster), single (Batch/Lot number: unknown) at the age of 73 years, in right arm for covid-19 immunisation; coviD-19 vaccine mrna (mrna 1273) (MODERNA COVID-19 VACCINE), on 05Apr2022 as dose 4 (booster), single (Lot number: 033B21A), in right arm for covid-19 immunisation. The patient's relevant medical history included: "Vaccine brand other=Moderna, Dose: 4/ Vaccine brand=Pfizer / BioNTech, Dose: 3, 2 and 1" (unspecified if ongoing), notes: Vaccine brand other=Moderna, Dose: 4/ Vaccine brand=Pfizer / BioNTech, Dose: 3, 2 and 1. The patient's concomitant medications were not reported. The following information was reported: VACCINATION FAILURE (medically significant), COVID-19 (medically significant) all with onset 2022, outcome "unknown" and all described as "Treatment of COVID-19". Therapeutic measures were taken as a result of vaccination failure, covid-19.  Clinical course: Serious, Seriousness criteria-results in death, Seriousness criteria-life threatening, Seriousness criteria- caused/prolonged hospitalization, Seriousness criteria- disabling/incapacitating, Seriousness criteria-congenital anomaly/birth defect reported as No. Report about COVID treatment Yes. If vaccine received and other medication in 2 weeks reported as Yes. Antiviral details Product: COVID 19 Treatment, brand: Paxlovid by Pfizer, Treatment start date: 30May2022, Treatment stop date: 02Jun2022, Lot number: GA3581, indication: Treatment of COVID-19. Known allergies reported as No. Other medical history reported as None.  The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.
Information has been received from a physician concerning a 26 year old female who on 31-MAY-2007 was vaccinated with a first dose of Gardasil (Lot number 0210U) expiry date 22-NOV-2009 injection in the right deltoid. Concomitant therapy was reported as none. The physician reported that within 10 minutes of receiving the first dose the patient fainted. It was also reported that, the patient "snapped out of it (time unspecified)" recovered. Medical attention was sought and at the time of reporting additional information was not provided. Follow-up information was received from the physician. The patient is not pregnant, was not hospitalized and medications were not given. The patient was given juice. Additional information is not available.
This spontaneous report as received from a consumer refers to a patient of unknown age and gender. No information regarding the patient's pertinent medical history, concomitant medications, drug reactions or allergies was provided. On an unknown date, the patient was vaccinated with a dose of GARDASIL (dose, frequency, route of administration, lot# and expiration date were not reported) or a dose of GARDASIL 9 (dose, frequency, route of administration, lot# and expiration date were not reported). It was unknown if product was GARDASIL or GARDASIL 9. On an unknown date, the patient experienced adverse event unspecified. The outcome of adverse event was unknown. The relatedness between the adverse event and therapy with GARDASIL or GARDASIL was not reported. This is one of six reports received from the same source.; Sender's Comments: US-009507513-1712USA014392: US-009507513-1712USA014393: US-009507513-1712USA014394: US-009507513-1712USA014396: US-009507513-1712USA013057: